Healius share price rallies amid corporate reset

An outgoing chair and a revitalised balance sheet. Healius is undergoing a makeover.

| More on:
Cropped shot of an attractive young female scientist working on her computer in the laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Healius Ltd (ASX: HLS) share price is rising this morning as the pathology and imaging company attempts to wipe its slate clean.

As the morning dew begins to dry, shares in the $90 million healthcare operator are up 3.8% to $1.38 — outpacing the more modest 0.75% increase mustered up by the All Ordinaries (ASX: XAO). The uptick places the company on track for a four-day green streak.

Spring cleaning sparks optimism

Spring is almost over, but not before embattled Healius breaks out the feather duster, so to speak. Yesterday, the company announced to the market that its chair, Jenny Macdonald, would be retiring at the completion of today's annual general meeting (AGM).

In her place, non-executive director Kate McKenzie will preside over Macdonald's former role until an official replacement is found. The decision to depart from the company follows nearly two years of disappointing performance for the diagnostic company, contending with the post-COVID slowdown.

The outgoing chair provided prepared comments for Healius' AGM today. Describing the reason for retiring, Macdonald stated:

Leadership stability will be crucial for Healius as it further progresses the work required to ensure that it is positioned to take advantage of the strong long term fundamentals for the Australian healthcare sector.

While we have made some important progress in the past 12 months, our plan requires stability to enable management to further progress our work and allow time for the benefits to emerge.

In stepping down as chair and opting to not seek re-election as a non-executive director of Healius, my objective is to provide stability for the business.

Investors might look at Healius more fondly today as the overhaul of its old self continues.

Refresh for the Healius share price

Healius shares have paid the price during the last two years. Since December 2021, the share price has crumbled to the tune of 72%.

The company's profit statement tells the story. In FY2022, Healius generated $292.4 million in net profits after tax. One year later, shareholders are suddenly staring at $380 million in losses.

As detailed by my colleague, James Mickleboro, Healius' deteriorating financial situation recently prompted it to raise capital at a steep discount of $1.20 per share. On 22 November, the company revealed it had secured $154 million from the institutional placement.

The funds will predominantly be used to lighten the load on Healius' balance sheet.

Today, the retail component of the capital raise opens, giving eligible shareholders the opportunity to get involved. As per this morning's announcement, new shares from the raise will be issued under a separate ticker ('HLSNB') due to the off-market takeover bid from Australian Clinical Labs (ACL).

The Healius share price is down 50.1% in 2023.

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Healthcare Shares

Why is the Sigma share price soaring 6%?

Sigma has upgraded its FY25 guidance ahead of the anticipated Chemist Warehouse merger completion.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Which ASX 200 healthcare share will pay the best dividend yield in 2025?

Earnings season is underway and dividend announcements are on investors' minds.

Read more »

A person is weighed down by a huge stack of coins, they have received a big dividend payout.
Dividend Investing

Looking to bag the record high ResMed dividend? You better hurry!

Unlike the majority of ASX 200 income stocks, ResMed pays dividends every quarter.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

3 reasons to buy CSL shares today

Two investment experts expect a big turnaround for CSL shares in 2025.

Read more »

Business people discussing project on digital tablet.
Healthcare Shares

Down 4%, is the ResMed share price in the buy zone?

Do analysts think investors should be buying the dip? Let's see what they are saying.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Guess which ASX 100 share is sinking 8% because of Trump's tariffs

Donald Trump has dealt this company a big blow. What's happening?

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Up 1,090% in a year, why is the Mesoblast share price leaping higher again on Friday?

Mesoblast shares have surged more than 1,000% over the last 12 months.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Earnings Results

ResMed shares rise on strong Q2 result

Let's see how this sleep treatment company performed during the second quarter.

Read more »